ClinicalTrials.gg
CompletedNCT05526716Updated Oct 29, 2025Results posted

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 When Administered Concomitantly With Influenza Vaccine in Adults 50 Years of Age or Older (V116-005, STRIDE-5)

A Phase 3 interventional study of V116 and QIV in Pneumonia, Pneumococcal, sponsored by Merck Sharp & Dohme LLC. Completed at 56 sites in United States. Open to participants aged 50 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-10-29.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,080
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies in Pneumonia, Pneumococcal with a site in United States — none open to participants now, none under way, none of them phase 3. Pneumonia, Pneumococcal · United States.

Enrollment
3rd of 11
1,080 · median 431
Started
2022
with 2 others
Phase 3
4 of 12
none open now
Registered
10th of 12
by date
Lead sponsor
4 of 12
Merck Sharp & Dohme LLC

Among the 12 studies in Pneumonia, Pneumococcal with a site in United States, this one is the 3rd largest by enrollment of the 11 interventional ones that give a count, is one of 3 that started in 2022, is one of 4 in phase 3, and was the 10th registered.

Pneumonia, Pneumococcal

44 studies on the registry are indexed under Pneumonia, Pneumococcal; 2 are open to participants now.

Browse Pneumonia, Pneumococcal studies →

Open to participants now

None of the 12 studies in Pneumonia, Pneumococcal with a site in United States is open now. The open studies under Pneumonia, Pneumococcal, anywhere →

Who these studies take

Of the 1 Pneumonia, Pneumococcal study recruiting now, 1 sets no upper age limit and none stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.

This study: 50 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies in Pneumonia, Pneumococcal with a site in United States as a file.
02

Study summary

This a study of V116 in adults ≥50 years of age who concomitantly received Influenza vaccine. The primary objectives of this study are to evaluate the safety, tolerability, and immunogenicity of V116 when administered concomitantly with Quadrivalent Influenza Vaccine (QIV) compared with V116 administered sequentially with QIV. The primary hypotheses state that immune responses to V116 and to QIV are non-inferior when administered concomitantly as compared with sequential administration as measured by serotype-specific opsonophagocytic activity (OPA) for V116 and hemagglutination inhibition (HAI) geometric mean titers (GMTs) for QIV, at 30 days postvaccination.

03

Conditions studied

  • Pneumonia, Pneumococcal
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Any underlying chronic conditions were assessed to be in stable condition per the investigator's judgment
  • Females: Not pregnant or a breast feeding and not a woman of (WOCBP) or a WOCBP agrees to use or remain abstinent

Exclusion criteria

Exclusion Criteria:

  • History of IPD or other culture-positive pneumococcal disease
  • Known or suspected impairment of immunological function
  • Receipt of systemic or therapy
  • Received any pneumococcal vaccine \<12 months prior to enrollment
  • Prior administration of PCV15 or PCV20
  • Received any influenza vaccine \<6 months prior to enrollment
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
1,080 participants (actual)

Study arms

  • Experimental
    Concomitant group (V116 + QIV followed by placebo)

    Participants will receive a single 0.5 mL intramuscular (IM) injection of V116 and a single 0.5 mL IM injection of QIV on Day 1 and a single 0.5 mL injection of placebo on Day 30

    Biological: V116 · Biological: QIV · Biological: Matching Placebo for V116

  • Experimental
    Sequential group (placebo + QIV followed by V116)

    Participants will receive a single 0.5 mL IM injection of QIV and a single 0.5 mL IM injection of placebo on Day 1 and a single 0.5 mL injection of V116 on Day 30

    Biological: V116 · Biological: QIV · Biological: Matching Placebo for V116

Interventions

  • BiologicalV116

    Pneumococcal 21-valent conjugate vaccine with 4 μg of each of the pneumococcal polysaccharides (PnPs) antigen: 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B in each 0.5 mL sterile solution

  • BiologicalQIV

    Single 0.5 mL IM injection

  • BiologicalMatching Placebo for V116

    Single 0.5 mL of sterile saline IM injection

06

What researchers measure

Primary outcomes

  1. Number of Participants With Solicited Injection-site Adverse Events (AEs)

    An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Solicited injection-site AEs included erythema, pain, and swelling.

    Time frame: Up to 5 days post-vaccination

  2. Number of Participants With Solicited Systemic AEs

    An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. Solicited systemic AEs include fatigue, headache, myalgia, and pyrexia.

    Time frame: Up to 5 days post-vaccination

  3. Percentage of Participants With Vaccine-related Serious Adverse Events (SAEs)

    A serious adverse event (SAE) is any untoward medical occurrence that, at any dose, results in death, is life threatening, requires inpatient hospitalization or prolongs existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is another important medical event. SAEs that were reported to be at least possibly related by the investigator to study vaccination are summarized.

    Time frame: Up to ~6 months postvaccination with V116

  4. Geometric Mean Titer (GMT) of Serotype-specific Opsonophagocytic Activity (OPA) Responses

    OPA for the serotypes in V116 were determined using a multiplexed opsonophagocytic assay (MOPA). Serotype-specific OPA GMTs (GMTs) (estimated) and GMT ratios with 95% CIs were calculated using a constrained longitudinal data analysis (cLDA) model utilizing data from both vaccination groups. Per the statistical analysis plan, the only CIs calculated were the between-group CIs (for the GMT ratios); within-group CIs were not calculated.

    Time frame: 30 days after V116 vaccination (Day 30 for concomitant group and Day 59 for sequential group)

  5. GMT of Influenza Strain-specific Hemagglutination Inhibition (HAI)

    GMTs for the 4 strains contained in QIV vaccine were determined using an HAI assay.

    Time frame: Day 30

Secondary outcomes

  1. Geometric Mean Concentration (GMC) of Serotype-specific Immunoglobulin G (IgG)

    The GMCs of serotype-specific IgG for the serotypes contained in V116 were determined using a pneumococcal electrochemiluminescence (Pn ECL) assay.

    Time frame: 30 days after V116 vaccination (Day 30 for concomitant group and Day 59 for sequential group)

  2. Geometric Mean Fold Rise (GMFR) Ratio of Serotype-specific OPA

    OPA for the serotypes in V116 were determined using a MOPA. GMFR ratio is defined as the geometric mean of the ratio of concentration at Day 30 after vaccination divided by concentration at baseline.

    Time frame: Baseline (Day 1 for the concomitant group and Day 30 for the sequential group) and Postvaccination (Day 30 for the concomitant group and Day 59 for the sequential group)

  3. GMFR Ratio of Serotype-specific IgG

    GMFR ratios for the serotype-specific IgG in V116 were determined using a Pn ECL.

    Time frame: Baseline (Day 1 for the concomitant group and Day 30 for the sequential group) and Postvaccination (Day 30 for the concomitant group and Day 59 for the sequential group)

  4. GMFR in Influenza Strain-specific HAI

    Activity for the 4 strains contained in QIV vaccine was determined using an HAI assay. GMFR is GMT 30 days after vaccination / GMT at Baseline.

    Time frame: Day 1 (Baseline) and Day 30 (Postvaccination)

  5. Percentage of Participants Who Seroconvert for Influenza Strain-specific HAI Titer ≥1:40

    The percentage of participants with seroconversion is presented. Activity for the 4 strains contained in QIV vaccine was determined using an HAI assay.

    Time frame: Day 30

07

Results

Posted Sep 5, 2024

Participant flow

This study was conducted at 56 centers in the United States.

Participant flow — Overall Study
MilestoneConcomitant Group (V116 + QIV Followed by Placebo)Sequential Group (Placebo + QIV Followed by V116)
Started540540
Vaccinated at visit 1536536
Vaccinated at visit 15340
Vaccinated at visit 10535
Vaccinated at visit 35220
Vaccinated at visit 30518
Completed510507
Not completed3033
Withdrew: Death12
Withdrew: Lost to follow-up1715
Withdrew: Physician decision01
Withdrew: Randomized by mistake without study treatment01
Withdrew: Withdrawal by subject1212
Withdrew: Not reported02

Outcome measures

PrimaryNumber of Participants With Solicited Injection-site Adverse Events (AEs)

An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Solicited injection-site AEs included erythema, pain, and swelling.

Time frame:
Up to 5 days post-vaccination
Reported as:
Count of participants · Participants
Number of Participants With Solicited Injection-site Adverse Events (AEs)
ParticipantsConcomitant Group (V116 + QIV Followed by Placebo)Sequential Group (Placebo + QIV Followed by V116)
Number of Participants With Solicited Injection-site Adverse Events (AEs)317314
PrimaryNumber of Participants With Solicited Systemic AEs

An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. Solicited systemic AEs include fatigue, headache, myalgia, and pyrexia.

Time frame:
Up to 5 days post-vaccination
Reported as:
Count of participants · Participants
Number of Participants With Solicited Systemic AEs
ParticipantsConcomitant Group (V116 + QIV Followed by Placebo)Sequential Group (Placebo + QIV Followed by V116)
Number of Participants With Solicited Systemic AEs219224
PrimaryPercentage of Participants With Vaccine-related Serious Adverse Events (SAEs)

A serious adverse event (SAE) is any untoward medical occurrence that, at any dose, results in death, is life threatening, requires inpatient hospitalization or prolongs existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is another important medical event. SAEs that were reported to be at least possibly related by the investigator to study vaccination are summarized.

Time frame:
Up to ~6 months postvaccination with V116
Reported as:
Count of participants · Participants
Percentage of Participants With Vaccine-related Serious Adverse Events (SAEs)
ParticipantsConcomitant Group (V116 + QIV Followed by Placebo)Sequential Group (Placebo + QIV Followed by V116)
Percentage of Participants With Vaccine-related Serious Adverse Events (SAEs)01
PrimaryGeometric Mean Titer (GMT) of Serotype-specific Opsonophagocytic Activity (OPA) Responses

OPA for the serotypes in V116 were determined using a multiplexed opsonophagocytic assay (MOPA). Serotype-specific OPA GMTs (GMTs) (estimated) and GMT ratios with 95% CIs were calculated using a constrained longitudinal data analysis (cLDA) model utilizing data from both vaccination groups. Per the statistical analysis plan, the only CIs calculated were the between-group CIs (for the GMT ratios); within-group CIs were not calculated.

Time frame:
30 days after V116 vaccination (Day 30 for concomitant group and Day 59 for sequential group)
Reported as:
Geometric mean · Titers
Geometric Mean Titer (GMT) of Serotype-specific Opsonophagocytic Activity (OPA) Responses
TitersConcomitant Group (V116 + QIV Followed by Placebo)Sequential Group (Placebo + QIV Followed by V116)
3209.2 (NA to NA)250.1 (NA to NA)
6A2056.4 (NA to NA)2608.2 (NA to NA)
7F2399.2 (NA to NA)3275.4 (NA to NA)
81508.9 (NA to NA)2135.7 (NA to NA)
9N5075.6 (NA to NA)7566.6 (NA to NA)
10A3033.6 (NA to NA)3966.2 (NA to NA)
11A2576.3 (NA to NA)4051.1 (NA to NA)
12F1869.9 (NA to NA)2449.5 (NA to NA)
15A4670.6 (NA to NA)6559.7 (NA to NA)
15C3426.0 (NA to NA)4832.6 (NA to NA)
16F5371.5 (NA to NA)7757.2 (NA to NA)
17F5783.8 (NA to NA)7924.3 (NA to NA)
19A1830.1 (NA to NA)2453.3 (NA to NA)
20A5172.8 (NA to NA)6986.9 (NA to NA)
22F3194.9 (NA to NA)4158.2 (NA to NA)
23A3358.2 (NA to NA)4319.9 (NA to NA)
23B934.3 (NA to NA)1664.5 (NA to NA)
24F2996.5 (NA to NA)4143.1 (NA to NA)
312997.4 (NA to NA)4390.6 (NA to NA)
33F9032.5 (NA to NA)10765.1 (NA to NA)
35B7701.4 (NA to NA)9940.2 (NA to NA)
Statistical analysis
  • Concomitant Group (V116 + QIV Followed by Placebo) vs Sequential Group (Placebo + QIV Followed by V116) · Geometric mean titers ratio (gmt ratio): 0.84 · 95% CI 0.72 to 0.97
  • Concomitant Group (V116 + QIV Followed by Placebo) vs Sequential Group (Placebo + QIV Followed by V116) · Gmt ratio: 0.79 · 95% CI 0.66 to 0.94
  • Concomitant Group (V116 + QIV Followed by Placebo) vs Sequential Group (Placebo + QIV Followed by V116) · Gmt ratio: 0.73 · 95% CI 0.63 to 0.85
  • Concomitant Group (V116 + QIV Followed by Placebo) vs Sequential Group (Placebo + QIV Followed by V116) · Gmt ratio: 0.71 · 95% CI 0.61 to 0.82
  • Concomitant Group (V116 + QIV Followed by Placebo) vs Sequential Group (Placebo + QIV Followed by V116) · Gmt ratio: 0.67 · 95% CI 0.57 to 0.79
  • Concomitant Group (V116 + QIV Followed by Placebo) vs Sequential Group (Placebo + QIV Followed by V116) · Gmt ratio: 0.76 · 95% CI 0.65 to 0.91
  • Concomitant Group (V116 + QIV Followed by Placebo) vs Sequential Group (Placebo + QIV Followed by V116) · Gmt ratio: 0.64 · 95% CI 0.54 to 0.75
  • Concomitant Group (V116 + QIV Followed by Placebo) vs Sequential Group (Placebo + QIV Followed by V116) · Gmt ratio: 0.76 · 95% CI 0.62 to 0.94
  • Concomitant Group (V116 + QIV Followed by Placebo) vs Sequential Group (Placebo + QIV Followed by V116) · Gmt ratio: 0.71 · 95% CI 0.60 to 0.85
  • Concomitant Group (V116 + QIV Followed by Placebo) vs Sequential Group (Placebo + QIV Followed by V116) · Gmt ratio: 0.71 · 95% CI 0.58 to 0.87
  • Concomitant Group (V116 + QIV Followed by Placebo) vs Sequential Group (Placebo + QIV Followed by V116) · Gmt ratio: 0.69 · 95% CI 0.59 to 0.81
  • Concomitant Group (V116 + QIV Followed by Placebo) vs Sequential Group (Placebo + QIV Followed by V116) · Gmt ratio: 0.73 · 95% CI 0.62 to 0.86
  • Concomitant Group (V116 + QIV Followed by Placebo) vs Sequential Group (Placebo + QIV Followed by V116) · Gmt ratio: 0.75 · 95% CI 0.65 to 0.85
  • Concomitant Group (V116 + QIV Followed by Placebo) vs Sequential Group (Placebo + QIV Followed by V116) · Gmt ratio: 0.74 · 95% CI 0.63 to 0.87
  • Concomitant Group (V116 + QIV Followed by Placebo) vs Sequential Group (Placebo + QIV Followed by V116) · Gmt ratio: 0.77 · 95% CI 0.65 to 0.91
  • Concomitant Group (V116 + QIV Followed by Placebo) vs Sequential Group (Placebo + QIV Followed by V116) · Gmt ratio: 0.78 · 95% CI 0.63 to 0.96
  • Concomitant Group (V116 + QIV Followed by Placebo) vs Sequential Group (Placebo + QIV Followed by V116) · Gmt ratio: 0.56 · 95% CI 0.44 to 0.72
  • Concomitant Group (V116 + QIV Followed by Placebo) vs Sequential Group (Placebo + QIV Followed by V116) · Gmt ratio: 0.72 · 95% CI 0.61 to 0.86
  • Concomitant Group (V116 + QIV Followed by Placebo) vs Sequential Group (Placebo + QIV Followed by V116) · Gmt ratio: 0.68 · 95% CI 0.56 to 0.83
  • Concomitant Group (V116 + QIV Followed by Placebo) vs Sequential Group (Placebo + QIV Followed by V116) · Gmt ratio: 0.84 · 95% CI 0.70 to 1.01
  • Concomitant Group (V116 + QIV Followed by Placebo) vs Sequential Group (Placebo + QIV Followed by V116) · Gmt ratio: 0.77 · 95% CI 0.67 to 0.89
PrimaryGMT of Influenza Strain-specific Hemagglutination Inhibition (HAI)

GMTs for the 4 strains contained in QIV vaccine were determined using an HAI assay.

Time frame:
Day 30
Reported as:
Geometric mean · Titers
GMT of Influenza Strain-specific Hemagglutination Inhibition (HAI)
TitersConcomitant Group (V116 + QIV Followed by Placebo)Sequential Group (Placebo + QIV Followed by V116)
A/H1N1268.23 (NA to NA)325.06 (NA to NA)
A/H3N2128.07 (NA to NA)163.06 (NA to NA)
B/Victoria70.02 (NA to NA)85.66 (NA to NA)
B/Yamagata31.80 (NA to NA)35.86 (NA to NA)
Statistical analysis
  • Concomitant Group (V116 + QIV Followed by Placebo) vs Sequential Group (Placebo + QIV Followed by V116) · Gmt ratio: 0.83 · 95% CI 0.70 to 0.97
  • Concomitant Group (V116 + QIV Followed by Placebo) vs Sequential Group (Placebo + QIV Followed by V116) · Gmt ratio: 0.79 · 95% CI 0.67 to 0.93
  • Concomitant Group (V116 + QIV Followed by Placebo) vs Sequential Group (Placebo + QIV Followed by V116) · Gmt ratio: 0.82 · 95% CI 0.70 to 0.95
  • Concomitant Group (V116 + QIV Followed by Placebo) vs Sequential Group (Placebo + QIV Followed by V116) · Gmt ratio: 0.89 · 95% CI 0.78 to 1.00
SecondaryGeometric Mean Concentration (GMC) of Serotype-specific Immunoglobulin G (IgG)

The GMCs of serotype-specific IgG for the serotypes contained in V116 were determined using a pneumococcal electrochemiluminescence (Pn ECL) assay.

Time frame:
30 days after V116 vaccination (Day 30 for concomitant group and Day 59 for sequential group)
Reported as:
Geometric mean · µg/mL
Geometric Mean Concentration (GMC) of Serotype-specific Immunoglobulin G (IgG)
µg/mLConcomitant Group (V116 + QIV Followed by Placebo)Sequential Group (Placebo + QIV Followed by V116)
30.60 (NA to NA)0.66 (NA to NA)
6A3.34 (NA to NA)3.58 (NA to NA)
7F3.91 (NA to NA)5.01 (NA to NA)
86.84 (NA to NA)8.38 (NA to NA)
9N4.99 (NA to NA)5.64 (NA to NA)
10A8.45 (NA to NA)10.70 (NA to NA)
11A4.83 (NA to NA)5.84 (NA to NA)
12F1.10 (NA to NA)1.31 (NA to NA)
15A8.83 (NA to NA)11.77 (NA to NA)
15C7.13 (NA to NA)8.39 (NA to NA)
16F1.93 (NA to NA)2.32 (NA to NA)
17F9.69 (NA to NA)11.44 (NA to NA)
19A6.41 (NA to NA)7.91 (NA to NA)
20A13.57 (NA to NA)16.52 (NA to NA)
22F3.13 (NA to NA)3.34 (NA to NA)
23A3.30 (NA to NA)3.87 (NA to NA)
23B4.24 (NA to NA)4.94 (NA to NA)
24F5.72 (NA to NA)6.71 (NA to NA)
312.50 (NA to NA)2.96 (NA to NA)
33F9.09 (NA to NA)11.26 (NA to NA)
35B15.73 (NA to NA)18.57 (NA to NA)
Statistical analysis
  • Concomitant Group (V116 + QIV Followed by Placebo) vs Sequential Group (Placebo + QIV Followed by V116) · Gmc ratio: 0.90 · 95% CI 0.80 to 1.02
  • Concomitant Group (V116 + QIV Followed by Placebo) vs Sequential Group (Placebo + QIV Followed by V116) · Gmc ratio: 0.93 · 95% CI 0.79 to 1.11
  • Concomitant Group (V116 + QIV Followed by Placebo) vs Sequential Group (Placebo + QIV Followed by V116) · Gmc ratio: 0.78 · 95% CI 0.67 to 0.90
  • Concomitant Group (V116 + QIV Followed by Placebo) vs Sequential Group (Placebo + QIV Followed by V116) · Gmc ratio: 0.82 · 95% CI 0.70 to 0.95
  • Concomitant Group (V116 + QIV Followed by Placebo) vs Sequential Group (Placebo + QIV Followed by V116) · Gmc ratio: 0.88 · 95% CI 0.75 to 1.05
  • Concomitant Group (V116 + QIV Followed by Placebo) vs Sequential Group (Placebo + QIV Followed by V116) · Gmc ratio: 0.79 · 95% CI 0.67 to 0.94
  • Concomitant Group (V116 + QIV Followed by Placebo) vs Sequential Group (Placebo + QIV Followed by V116) · Gmc ratio: 0.83 · 95% CI 0.72 to 0.96
  • Concomitant Group (V116 + QIV Followed by Placebo) vs Sequential Group (Placebo + QIV Followed by V116) · Gmc ratio: 0.83 · 95% CI 0.69 to 1.01
  • Concomitant Group (V116 + QIV Followed by Placebo) vs Sequential Group (Placebo + QIV Followed by V116) · Gmc ratio: 0.75 · 95% CI 0.63 to 0.90
  • Concomitant Group (V116 + QIV Followed by Placebo) vs Sequential Group (Placebo + QIV Followed by V116) · Gmc ratio: 0.85 · 95% CI 0.71 to 1.02
  • Concomitant Group (V116 + QIV Followed by Placebo) vs Sequential Group (Placebo + QIV Followed by V116) · Gmc ratio: 0.83 · 95% CI 0.70 to 0.99
  • Concomitant Group (V116 + QIV Followed by Placebo) vs Sequential Group (Placebo + QIV Followed by V116) · Gmc ratio: 0.85 · 95% CI 0.72 to 0.99
  • Concomitant Group (V116 + QIV Followed by Placebo) vs Sequential Group (Placebo + QIV Followed by V116) · Gmc ratio: 0.81 · 95% CI 0.71 to 0.93
  • Concomitant Group (V116 + QIV Followed by Placebo) vs Sequential Group (Placebo + QIV Followed by V116) · Gmc ratio: 0.82 · 95% CI 0.70 to 0.97
  • Concomitant Group (V116 + QIV Followed by Placebo) vs Sequential Group (Placebo + QIV Followed by V116) · Gmc ratio: 0.94 · 95% CI 0.80 to 1.10
  • Concomitant Group (V116 + QIV Followed by Placebo) vs Sequential Group (Placebo + QIV Followed by V116) · Gmc ratio: 0.85 · 95% CI 0.70 to 1.03
  • Concomitant Group (V116 + QIV Followed by Placebo) vs Sequential Group (Placebo + QIV Followed by V116) · Gmc ratio: 0.86 · 95% CI 0.72 to 1.02
  • Concomitant Group (V116 + QIV Followed by Placebo) vs Sequential Group (Placebo + QIV Followed by V116) · Gmc ratio: 0.85 · 95% CI 0.69 to 1.05
  • Concomitant Group (V116 + QIV Followed by Placebo) vs Sequential Group (Placebo + QIV Followed by V116) · Gmc ratio: 0.84 · 95% CI 0.72 to 0.99
  • Concomitant Group (V116 + QIV Followed by Placebo) vs Sequential Group (Placebo + QIV Followed by V116) · Gmc ratio: 0.81 · 95% CI 0.69 to 0.94
  • Concomitant Group (V116 + QIV Followed by Placebo) vs Sequential Group (Placebo + QIV Followed by V116) · Gmc ratio: 0.85 · 95% CI 0.72 to 0.99
SecondaryGeometric Mean Fold Rise (GMFR) Ratio of Serotype-specific OPA

OPA for the serotypes in V116 were determined using a MOPA. GMFR ratio is defined as the geometric mean of the ratio of concentration at Day 30 after vaccination divided by concentration at baseline.

Time frame:
Baseline (Day 1 for the concomitant group and Day 30 for the sequential group) and Postvaccination (Day 30 for the concomitant group and Day 59 for the sequential group)
Reported as:
Geometric mean · Ratio
Geometric Mean Fold Rise (GMFR) Ratio of Serotype-specific OPA
RatioConcomitant Group (V116 + QIV Followed by Placebo)Sequential Group (Placebo + QIV Followed by V116)
35.2 (4.6 to 5.9)6.7 (5.9 to 7.6)
6A9.4 (8.0 to 11.1)13.2 (11.0 to 15.8)
7F8.1 (6.8 to 9.6)9.8 (8.1 to 11.9)
89.6 (8.0 to 11.6)10.9 (9.0 to 13.3)
9N6.2 (5.3 to 7.4)8.2 (6.9 to 9.6)
10A10.4 (8.7 to 12.6)11.1 (9.2 to 13.4)
11A13.0 (10.7 to 15.9)15.2 (12.4 to 18.7)
12F37.4 (30.8 to 45.5)46.8 (37.7 to 58.0)
15A7.6 (6.4 to 9.1)8.9 (7.3 to 11.0)
15C25.0 (20.5 to 30.4)30.2 (24.5 to 37.3)
16F9.9 (8.6 to 11.4)11.9 (10.3 to 13.7)
17F10.4 (8.8 to 12.4)15.1 (12.8 to 18.0)
19A3.6 (3.2 to 4.2)5.2 (4.5 to 6.1)
20A6.7 (5.7 to 7.7)8.5 (7.3 to 9.9)
22F13.7 (11.2 to 16.8)16.9 (13.6 to 20.9)
23A17.0 (14.0 to 20.8)25.5 (20.4 to 31.8)
23B42.9 (35.4 to 52.0)60.9 (48.9 to 75.9)
24F31.6 (26.1 to 38.3)33.2 (27.3 to 40.5)
3129.8 (24.5 to 36.2)40.3 (32.5 to 49.9)
33F5.5 (4.7 to 6.4)6.3 (5.3 to 7.4)
35B5.5 (4.7 to 6.4)6.3 (5.3 to 7.4)
SecondaryGMFR Ratio of Serotype-specific IgG

GMFR ratios for the serotype-specific IgG in V116 were determined using a Pn ECL.

Time frame:
Baseline (Day 1 for the concomitant group and Day 30 for the sequential group) and Postvaccination (Day 30 for the concomitant group and Day 59 for the sequential group)
Reported as:
Geometric mean · Ratio
GMFR Ratio of Serotype-specific IgG
RatioConcomitant Group (V116 + QIV Followed by Placebo)Sequential Group (Placebo + QIV Followed by V116)
33.6 (3.3 to 4.0)4.1 (3.7 to 4.6)
6A7.8 (6.9 to 8.9)8.4 (7.3 to 9.7)
7F5.6 (5.0 to 6.4)7.2 (6.3 to 8.2)
87.1 (6.2 to 8.1)8.7 (7.5 to 10.1)
9N8.0 (6.9 to 9.2)9.0 (7.8 to 10.5)
10A9.3 (8.1 to 10.6)11.4 (9.9 to 13.1)
11A5.7 (5.1 to 6.4)7.2 (6.3 to 8.1)
12F6.9 (6.0 to 8.0)7.9 (6.8 to 9.1)
15A14.2 (12.3 to 16.4)19.5 (16.8 to 22.5)
15C11.0 (9.6 to 12.6)12.3 (10.6 to 14.2)
16F11.1 (9.8 to 12.6)13.4 (11.8 to 15.2)
17F10.9 (9.5 to 12.5)13.2 (11.5 to 15.3)
19A3.0 (2.7 to 3.4)3.9 (3.5 to 4.5)
20A7.4 (6.5 to 8.4)8.9 (7.7 to 10.2)
22F8.2 (7.1 to 9.4)9.0 (7.8 to 10.3)
23A15.5 (13.6 to 17.6)17.3 (15.0 to 20.0)
23B10.2 (8.9 to 11.6)10.9 (9.4 to 12.6)
24F20.2 (17.4 to 23.4)23.5 (20.3 to 27.3)
3112.6 (11.2 to 14.2)15.3 (13.5 to 17.3)
33F5.1 (4.5 to 5.7)6.2 (5.4 to 7.1)
35B12.3 (10.9 to 13.9)14.9 (13.0 to 17.1)
SecondaryGMFR in Influenza Strain-specific HAI

Activity for the 4 strains contained in QIV vaccine was determined using an HAI assay. GMFR is GMT 30 days after vaccination / GMT at Baseline.

Time frame:
Day 1 (Baseline) and Day 30 (Postvaccination)
Reported as:
Geometric mean · Ratio
GMFR in Influenza Strain-specific HAI
RatioConcomitant Group (V116 + QIV Followed by Placebo)Sequential Group (Placebo + QIV Followed by V116)
A/H1N14.5 (3.9 to 5.2)5.7 (4.9 to 6.7)
A/H3N25.6 (5.0 to 6.3)7.1 (6.3 to 8.1)
B/Victoria3.6 (3.3 to 4.0)4.5 (4.0 to 5.1)
B/Yamagata1.9 (1.8 to 2.1)2.2 (2.1 to 2.4)
SecondaryPercentage of Participants Who Seroconvert for Influenza Strain-specific HAI Titer ≥1:40

The percentage of participants with seroconversion is presented. Activity for the 4 strains contained in QIV vaccine was determined using an HAI assay.

Time frame:
Day 30
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Seroconvert for Influenza Strain-specific HAI Titer ≥1:40
Percentage of ParticipantsConcomitant Group (V116 + QIV Followed by Placebo)Sequential Group (Placebo + QIV Followed by V116)
A/H1N147.1 (42.6 to 51.7)55.6 (51.0 to 60.1)
A/H3N263.8 (59.4 to 68.1)68.3 (63.9 to 72.4)
B/Victoria52.3 (47.7 to 56.8)54.1 (49.6 to 58.7)
B/Yamagata23.3 (19.6 to 27.4)29.9 (25.8 to 34.2)

Adverse events

Collected over Up to ~6 months postvaccination with V116. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Concomitant Group (V116 + QIV Followed by Placebo)1/540 (0.2%)10/534 (1.9%)362/534 (67.8%)
Sequential Group (Placebo + QIV Followed by V116)2/540 (0.4%)17/535 (3.2%)348/535 (65%)
Most frequent serious events
Showing 10 of 35
Most frequent serious events
EventConcomitant Group (V116 + QIV Followed by Placebo)Sequential Group (Placebo + QIV Followed by V116)
Pulmonary embolismRespiratory, thoracic and mediastinal disorders2/5340/535
Blood loss anaemiaBlood and lymphatic system disorders1/5340/535
Atrial fibrillationCardiac disorders1/5341/535
Gastric ulcer haemorrhageGastrointestinal disorders1/5340/535
PancreatitisGastrointestinal disorders1/5340/535
DiverticulitisInfections and infestations1/5340/535
InfluenzaInfections and infestations1/5340/535
Wound infectionInfections and infestations1/5340/535
Ankle fractureInjury, poisoning and procedural complications1/5340/535
HypokalaemiaMetabolism and nutrition disorders1/5340/535
Most frequent other events
Most frequent other events
EventConcomitant Group (V116 + QIV Followed by Placebo)Sequential Group (Placebo + QIV Followed by V116)
Injection site painGeneral disorders310/534303/535
FatigueGeneral disorders162/534175/535
HeadacheNervous system disorders109/534120/535
MyalgiaMusculoskeletal and connective tissue disorders74/53480/535
Injection site swellingGeneral disorders68/53466/535
Injection site erythemaGeneral disorders63/53460/535

Baseline characteristics

All vaccinated participants are included.

Age, Continuous
Age, Continuous(years)Concomitant Group (V116 + QIV Followed by Placebo)Sequential Group (Placebo + QIV Followed by V116)Total
Mean64.2 ± 8.464.2 ± 8.464.2 ± 8.4
Sex: Female, Male
Sex: Female, Male(Participants)Concomitant Group (V116 + QIV Followed by Placebo)Sequential Group (Placebo + QIV Followed by V116)Total
Female297287584
Male239249488
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Concomitant Group (V116 + QIV Followed by Placebo)Sequential Group (Placebo + QIV Followed by V116)Total
Hispanic or Latino127125252
Not Hispanic or Latino403409812
Unknown or Not Reported628
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Concomitant Group (V116 + QIV Followed by Placebo)Sequential Group (Placebo + QIV Followed by V116)Total
American Indian or Alaska Native145
Asian31013
Native Hawaiian or Other Pacific Islander112
Black or African American107101208
White410412822
More than one race13821
Unknown or Not Reported101
08

Study locations

56 sites
  • Central Phoenix Medical Clinic-Synexus Clinical Research US ( Site 0012)
    Phoenix, Arizona 85020, United States
  • Hope Clinical Research, Inc. ( Site 0070)
    Canoga Park, California 91303, United States
  • Paradigm Clinical Research Centers, Inc ( Site 0024)
    La Mesa, California 91942, United States
  • Catalina Research Institute, LLC ( Site 0067)
    Montclair, California 91763, United States
  • WR- PRI, LLC ( Site 0044)
    Newport Beach, California 92620, United States
  • Carbon Health - North Hollywood - NoHo West ( Site 0016)
    North Hollywood, California 91606, United States
  • Valley Clinical Trials, Inc. ( Site 0002)
    Northridge, California 91325, United States
  • Artemis Institute for Clinical Research ( Site 0023)
    San Diego, California 92103, United States
  • WR-MCCR, LLC ( Site 0033)
    San Diego, California 92120, United States
  • California Research Foundation ( Site 0005)
    San Diego, California 92123, United States
  • Diablo Clinical Research, Inc. ( Site 0020)
    Walnut Creek, California 94598, United States
  • Velocity Clinical Research, Hallandale Beach ( Site 0064)
    Hallandale, Florida 33009, United States
  • Indago Research & Health Center, Inc ( Site 0029)
    Hialeah, Florida 33012, United States
  • East Coast Institute for Research, LLC ( Site 0013)
    Jacksonville, Florida 32216, United States
  • Health Awareness ( Site 0034)
    Jupiter, Florida 33458, United States
  • Optimal Research ( Site 0008)
    Melbourne, Florida 32934, United States
  • Suncoast Research Group-Clinical Department ( Site 0062)
    Miami, Florida 33135, United States
  • Suncoast Research Associates ( Site 0041)
    Miami, Florida 33173, United States
  • Alpha Science Research ( Site 0042)
    Miami, Florida 33186, United States
  • Lakes Research ( Site 0063)
    Miami Lakes, Florida 33014, United States
  • Triple O Research Institute, P.A ( Site 0054)
    West Palm Beach, Florida 33407, United States
  • East Coast Institute for Research - Canton ( Site 0004)
    Canton, Georgia 30114, United States
  • Clinical Research Atlanta ( Site 0068)
    Stockbridge, Georgia 30281, United States
  • Synexus Clinical Research US, Inc. ( Site 0072)
    Chicago, Illinois 60602, United States
  • Healthcare Research Network - Chicago ( Site 0014)
    Flossmoor, Illinois 60422, United States
  • Centennial Medical Group ( Site 0035)
    Elkridge, Maryland 21075, United States
  • Healthcare Research Network - St. Louis ( Site 0011)
    St Louis, Missouri 63042, United States
  • Radiant Research ( Site 0073)
    St Louis, Missouri 63141, United States
  • Alivation Research-Primary Care ( Site 0066)
    Lincoln, Nebraska 68526, United States
  • WR-CRCN, LLC ( Site 0018)
    Las Vegas, Nevada 89106, United States
  • Axces Research ( Site 0037)
    Santa Fe, New Mexico 87505, United States
  • Smith Allergy and Asthma Specialists-Certified Research Associates ( Site 0019)
    Cortland, New York 13045, United States
  • Synexus Clinical Research US, Inc - New York ( Site 0053)
    New York, New York 10017, United States
  • Rochester Clinical Research, Inc. ( Site 0055)
    Rochester, New York 14609, United States
  • Meridian Clinical Research, LLC ( Site 0032)
    Vestal, New York 13850, United States
  • Carolina Institute for Clinical Research ( Site 0047)
    Fayetteville, North Carolina 28303, United States
  • M3 Wake Research Associates ( Site 0040)
    Raleigh, North Carolina 27612, United States
  • CTI Clinical Research Center ( Site 0071)
    Cincinnati, Ohio 45212, United States
  • Velocity Clinical Research, Medford ( Site 0060)
    Medford, Oregon 97504, United States
  • Hatboro Medical Associates / CCT Research ( Site 0065)
    Hatboro, Pennsylvania 19040, United States
  • Velocity Clinical Research, Providence ( Site 0021)
    East Greenwich, Rhode Island 02818, United States
  • Velocity Clinical Research, Anderson ( Site 0077)
    Anderson, South Carolina 29621, United States
  • Velocity Clinical Research, Columbia ( Site 0058)
    Columbia, South Carolina 29204, United States
  • Holston Medical Group-Clinical Research ( Site 0028)
    Bristol, Tennessee 37620, United States
  • Holston Medical Group-Clinical Research ( Site 0009)
    Kingsport, Tennessee 37660, United States
  • Clinical Research Associates Inc ( Site 0026)
    Nashville, Tennessee 37203, United States
  • Optimal Research ( Site 0015)
    Austin, Texas 78705, United States
  • Headlands Research - Brownsville ( Site 0069)
    Brownsville, Texas 78526, United States
  • Benchmark Research ( Site 0025)
    Fort Worth, Texas 76135, United States
  • New Horizon Medical Group ( Site 0078)
    Houston, Texas 77042, United States
  • Innovative Medical Research of Texas ( Site 0079)
    Houston, Texas 77065, United States
  • LinQ Research ( Site 0074)
    Pearland, Texas 77584, United States
  • Synexus Clinical Research US, Inc. ( Site 0001)
    Murray, Utah 84123, United States
  • Alliance for Multispecialty Research, LLC ( Site 0051)
    South Jordan, Utah 84095, United States
  • Arthritis Northwest, PLLC ( Site 0059)
    Spokane, Washington 99204, United States
  • Velocity Clinical Research, Spokane ( Site 0050)
    Spokane, Washington 99204, United States
09

References and documents

Publications

  • Omole T, Weinberg AS, Azizad M, Greenberg D, Grijalva CG, Orenstein WA, Euler D, Fernsler D, Park J, Li J, Platt HL; STRIDE-5 study group. A phase 3 randomized, double-blind clinical study to evaluate the safety and immunogenicity of V116 when administered concomitantly with influenza vaccine in adults 50 years of age or older. Vaccine. 2025 Aug 30;62:127514. doi: 10.1016/j.vaccine.2025.127514. Epub 2025 Jul 25. PubMed 40714528 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2022 to primary completion in Jun 2023, 8 months.

Results were first posted in Sep 2024, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 31, 2022
First posted
Sep 2, 2022
StartActual
Sep 23, 2022
Primary completionActual
Jun 21, 2023
CompletionActual
Jun 21, 2023
Results first posted
Sep 5, 2024
Last update
Oct 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05526716
Responsible party
Sponsor
First posted
Sep 2, 2022
Start date
Sep 23, 2022
Primary completion
Jun 21, 2023
Completion
Jun 21, 2023
Results posted
Sep 5, 2024
Last update
Oct 29, 2025

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pneumococcal 21-Valent Conjugate Vaccine

Start the discussion